Interesting Tidbits From Avigilon Corp.’s Latest Report

Strong results and a promising licensing opportunity leave Avigilon Corp. (TSX:AVO) looking good.

Since the end of February, Avigilon Corp.’s (TSX:AVO) shares have increased 15%, driven by strong fourth-quarter and year-end 2015 results. Let’s first take a look at the results and some interesting tidbits that speak to the state of the company and the future.

Revenue growth is strong but decelerating

The posted revenue-growth rate for the year was 36%, but on a constant-currency basis, the growth rate was a more modest 21%. For the quarter, the posted revenue-growth rate was 37%, while the constant-currency growth rate was 27%. The revenue-growth rate is decelerating, but it compares nicely to last quarter’s 16% growth and to the industry-growth rate of below 10%, which means that the company continues to capture market share.

Margins are lower but are holding up nicely

As expected, sales and marketing as well as general and administrative expenses increased in 2015, but EBITDA margins were still strong at 19.1% in the fourth quarter versus 21.6% in the same period last year.

Increased confidence in the revenue target

Management is getting closer to its goal of a revenue run rate of $500 million by the end of 2016 and have reiterated their confidence that this goal will be achieved.

A switch to U.S. dollars reporting

It’s worth noting as well that management has decided to report in U.S. dollars starting in 2016 as roughly 70% of revenue is, in fact, in U.S. dollars. This is a welcome change as it will minimize foreign exchange gains and losses and stabilize revenue, EBITDA, and margins.

Rights plan

Reflecting management’s opinion that the stock is undervalued and to therefore avoid being the target of a hostile takeover, they entered into a rights plan, or “poison pill.” Shareholders will vote on this at the company’s 2016 annual general meeting.

Licensing revenue opportunity

Avigilon currently has over 600 patents related mostly to its video analytics technology. The company is pursuing licensing these patents and currently has a licensing revenue stream, but it is not significant as of yet.

During the fourth quarter, a patent program was launched called the Early Adopter Plan, whereby first movers entering into a patent licensing agreement with Avigilon will get preferential rates. The royalty agreements are from three to 20 years with more savings for the client the longer the term. Management has said that the response to this program has exceeded their expectations and they are very encouraged by this.

Management believes that licensing revenue will be more meaningful to Avigilon in 2017 and beyond.

In closing, while volatility will probably still be an issue with the stock and the company’s results due to the fast-growing, highly dynamic industry it is in, Avigilon is building momentum and growing at above market rates, and so the current 2% market share should increase if they continue on this trajectory.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Karen Thomas owns shares of Avigilon Corp. Avigilon is a recommendation of Stock Advisor Canada.

More on Tech Stocks

Man data analyze
Tech Stocks

3 Reasons Celestica Stock Is a Screaming Buy Now

These three reasons make Celestica stock a screaming buy for long-term investors.

Read more »

profit rises over time
Dividend Stocks

These 2 Dow Stocks Are Set to Soar in 2025 and Beyond

Two Dow Jones stocks are screaming buys but Canadians must hold them in an RRSP or RRIF to avoid paying…

Read more »

telehealth stocks
Tech Stocks

Well Health Stock: Buy, Sell, or Hold?

Another record-breaking quarter and strong demand sets the stage for continued momentum for Well Health stock.

Read more »

3 colorful arrows racing straight up on a black background.
Dividend Stocks

TSX Stocks Soaring Higher With No Signs of Slowing

Three TSX stocks continue to beat the market and could soar higher in an improving investment landscape.

Read more »

profit rises over time
Tech Stocks

2 Non-AI Tech Stocks to Buy in November for Better Returns

Not all AI stocks are riding the hype train, and for many investors, well-understood and predictable growth stocks might be…

Read more »

worry concern
Tech Stocks

In a Few Years, You’ll Probably Regret Not Owning BlackBerry Stock

Here’s why I believe BlackBerry could be one of the most overlooked Canadian tech stocks right now.

Read more »

A worker uses a double monitor computer screen in an office.
Tech Stocks

Is Constellation Software Stock a Buy for its 0.25% Dividend Yield?

Here's what investors may want to consider when it comes to Dollarama (TSX:DOL) and its relatively low dividend yield.

Read more »

Nurse talks with a teenager about medication
Tech Stocks

Shares of WELL Health Just Zoomed. Is It a Buy?

Given its improving financials and healthy growth prospects, WELL Health could deliver superior returns over the next three years.

Read more »